The FDA has declared the end of the two-year shortages of Eli Lilly’s Mounjaro and Zepbound — used to treat diabetes and weight loss, respectively — and has reaffirmed its decision to halt the production of compounded versions of the drugs, Bloomberg reported Dec. 19.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
